Coronaviruses have found another door into human cells, and it is one that scientists were not watching.
A bat virus isolated from heart-nosed bats in Kenya can latch onto a human protein called CEACAM6, a receptor found on cells lining the gut and lungs, according to a peer-reviewed study published in Nature in early 2026. No previously characterized coronavirus had been shown to use this molecule to enter cells. The discovery forces a rethink of which bat viruses deserve surveillance attention and which parts of the human body might be vulnerable to future spillovers.
The virus, an alphacoronavirus designated CcCoV-KY43, belongs to a branch of the coronavirus family tree that has largely been overlooked in pandemic preparedness planning. Since SARS emerged in 2003, followed by MERS in 2012 and SARS-CoV-2 in 2019, the spotlight has stayed on betacoronaviruses. Yet alphacoronaviruses already account for at least two viruses that infect people: the common-cold virus 229E and the respiratory pathogen NL63. This study suggests the group may have more tricks than anyone realized.
A third receptor, hiding in plain sight
Until now, scientists knew of two receptor systems that alphacoronaviruses use to break into human cells. The cold virus 229E binds a protein called APN. NL63, like the more dangerous SARS-CoV-2, uses ACE2. CcCoV-KY43 uses neither. Instead, it targets CEACAM6 (also called CD66c), a cell adhesion molecule with Gene ID 4680 that sits on the surface of intestinal and airway cells.
The research team identified this pathway by synthesizing spike proteins from bat coronaviruses cataloged in GenBank and screening them against panels of human receptors using pseudovirus systems, lab-built particles that mimic viral entry without posing infection risk. When CcCoV-KY43’s spike locked onto CEACAM6, the researchers ran a series of confirmation tests. Cells engineered to produce high levels of CEACAM6 were readily entered by the pseudovirus. Cells with the receptor knocked out resisted infection. Blocking antibodies targeting CEACAM6 sharply reduced entry as well.
The team also tested whether the virus could use related proteins in the same receptor family, including CEACAM1 and CEACAM5. It could not, at least not efficiently. That specificity suggests CcCoV-KY43 has evolved a precise molecular fit for CEACAM6, a detail that carries its own implications: relatively small mutations in the spike, or natural variation in the human receptor, could shift susceptibility in ways that are hard to predict without further study.
Structural confirmation came from X-ray crystallography. The atomic coordinates of the CcCoV-KY43 spike bound to human CEACAM6 were deposited in the Protein Data Bank under entry 9RCS, giving any lab in the world the data needed to independently verify how tightly the virus grips its target.
Why alphacoronaviruses have been a blind spot
Pandemic preparedness funding and research infrastructure have overwhelmingly favored betacoronaviruses since SARS. Alphacoronaviruses, which tend to cause milder illness in humans, have attracted far less scrutiny. Expert commentary published alongside the study in Nature describes receptor recognition as a key species barrier and notes that alphacoronavirus entry mechanisms remain comparatively understudied.
That gap looks more consequential in light of what is already known about Kenyan bat populations. Surveillance work published in Virus Evolution has documented a striking diversity of alphacoronaviruses in Kenyan bats, including relatives of both 229E and NL63. The same research recorded recombination events among those viruses, meaning lineages circulating in bat roosts are actively swapping genetic material. Recombination is the mechanism by which a virus can pick up a new spike protein or other molecular tools that help it jump into a different host species.
High viral diversity, active recombination, and a newly confirmed human-compatible receptor add up to a scenario worth watching. Alphacoronaviruses that cause mild or asymptomatic infections are also harder to detect through routine clinical testing, which means early signals of adaptation toward humans could go unnoticed, particularly in regions with limited diagnostic infrastructure.
What remains uncertain
The study shows that CcCoV-KY43 can bind to and enter human cells under laboratory conditions. It does not show that the virus can replicate efficiently in human tissue, spread between people, or cause disease. Receptor binding is one step in a multi-step infection process, and clearing that hurdle does not guarantee a virus can complete its life cycle in a new host.
No quantitative risk assessment from the World Health Organization, the U.S. Centers for Disease Control and Prevention, or any other public health body has addressed the probability of a CEACAM6-mediated spillover event. The study itself does not model transmission scenarios or assign likelihood scores. The practical distance between “can enter a cell” and “can cause an outbreak” remains unmeasured.
Field data on human contact with heart-nosed bats in Kenya is sparse. Surveillance confirms that Kenyan bat populations harbor diverse coronaviruses, but how often people encounter these specific bat species through farming, cave use, or bushmeat handling is not well quantified. Contact rates shape spillover probability as much as receptor compatibility does.
It is also unclear how widely CcCoV-KY43 or closely related viruses circulate beyond the original sampling sites. Bat virome surveys typically cover a small fraction of roosts and seasons, leaving open the possibility that similar CEACAM6-using viruses exist across a broader geographic range or, conversely, that this lineage is rare and localized.
What this changes for preparedness
The practical lesson is not that CcCoV-KY43 is about to cause a pandemic. It is that the coronavirus playbook needs updating. Vaccines, antiviral drugs, and diagnostic tests developed in response to SARS-CoV-2 were built around ACE2-binding betacoronaviruses. A virus that enters cells through CEACAM6 could sidestep some of those tools entirely. Broadening countermeasure design to account for alternative receptor pathways is the kind of adjustment that is far cheaper to make before a crisis than during one.
The discovery also reinforces the value of basic virology that can seem abstract until it suddenly is not. Mapping obscure bat viruses, characterizing their spikes, and solving crystal structures like the CEACAM6 complex builds a reference library that scientists can consult rapidly when a new pathogen surfaces. That kind of preemptive work helped researchers identify SARS-CoV-2’s receptor within weeks of the virus being sequenced in January 2020.
For now, CcCoV-KY43 sits in the space between a laboratory finding and a public health threat. Closing that gap will require deeper surveillance of Kenyan bat populations, studies testing whether the virus can replicate in human airway and gut tissue, and formal risk assessments from agencies equipped to weigh the epidemiological variables. Until that work is done, the study stands as a pointed reminder: coronaviruses have been exploring entry strategies that humans have barely begun to catalog.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
